文献速递腹部介入CT

结直肠癌肝转移患者行大范围肝切除后肝内复发接受挽救性射频消融的中期结局

Salvage RFA in patients with intrahepatic recurrence after major hepatic surgery for colorectal cancer liver metastases: mid-term outcome.
PubMed 文献 · Eur Radiol · 2019-09-06

观察性研究纳入23例大范围肝切除后肝内复发的结直肠癌肝转移患者,行CT引导挽救性射频消融;消融后中位肝内无进展生存期8个月,与末次手术后至复发的中位时间5个月相似(p=0.238),中位总生存期37个月,1年、3年、5年生存率分别为100%、57%、24%。

要点

  • 大范围肝切除后肝内复发的结直肠癌肝转移患者,挽救性射频消融后中位肝内无进展生存期仅8个月。
  • 消融后15/23(65%)患者在1年内出现新发肝内转移灶。
  • 消融后中位总生存期37个月,3年生存率57%,5年生存率24%。

核心结论

  • 大范围肝切除后肝内复发的结直肠癌肝转移患者,挽救性射频消融后仍会出现肝内复发,且复发间隔时间与手术后至复发的时间相似;但部分患者仍可获得长期肝内无进展生存。

研究设计与样本

  • 观察性研究,纳入23例连续患者(平均年龄59±9岁,男/女14/9),均为单次(11/23)或多轮(12/23)大范围肝手术后出现肝内复发的结直肠癌肝转移患者;肿瘤最多3个、最大径至多3cm且无相关肝外疾病者接受CT引导射频消融;采用Kaplan-Meier法比较挽救性射频消融后与同一患者末次手术后至肝内复发诊断之间的肝内无进展生存期和总生存期。

诊断标准与关键数值

  • 中位随访26个月(范围12-103个月);射频消融后中位肝内无进展生存期8个月(范围1-81个月),同一患者末次手术后至射频消融前中位肝内无进展生存期5个月(范围1-23个月),两者相似(p=0.238;Mood中位数检验);射频消融后1年内15/23(65%)患者出现新发肝内转移;中位总生存期37个月,1年生存率100%、3年生存率57%、5年生存率24%;未观察到主要并发症。

临床应用与阅片要点

  • 对大范围肝切除后肝内复发的结直肠癌肝转移患者行CT引导挽救性射频消融后,约三分之二患者在1年内出现新发肝内转移,但部分患者仍可获得长期肝内无进展生存,消融后需关注肝内新发病灶。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the mid-term outcome of salvage radiofrequency ablation (RFA) treatment in patients who exhibited intrahepatic recurrence after major hepatectomy for colorectal liver metastases (CRCLM).

METHODS: Observational study on 23 consecutive patients (mean age 59 ± 9 years; 14/9 male/female) who, after a single (11/23) or multiple rounds (12/23) of major hepatic surgery, developed recurrent CRCLM in the liver remnant. Patients with a maximum of three metastases measuring up to 3 cm, and without relevant extrahepatic disease, underwent CT-guided RFA. Using the Kaplan-Meier-method, median intrahepatic progression-free-survival (ihPFS) and overall survival (OS) times after salvage RFA were compared with the same patients' time between the respective last round of surgery and diagnosis of intrahepatic recurrence leading to RFA.

RESULTS: Median follow-up was 26 months (range 12-103 months). Median ihPFS time after RFA was 8 months (range 1-81 months). Median ihPFS time after the respective last round of surgery and RFA in the same patients had been 5 months (range 1-23 months), thus yielding similar ihPFS times after surgery vs. after salvage RFA (p = 0.238; Mood's median test). After RFA, 15/23 (65%) of patients developed new hepatic metastases within the first year post-RFA. Median OS was 37 months, with a 1-year OS rate of 100%, 3-year OS rate of 57%, and 5-year OS rate of 24%. No major complications were observed.

CONCLUSIONS: Patients who exhibit intrahepatic recurrence of CRCLM after major hepatectomy will experience intrahepatic recurrence after salvage RFA as well, and after similar time intervals. However, long-term ihPFS may still be achieved in some patients.

KEY POINTS: • Patients who exhibit intrahepatic recurrence of colorectal liver metastases after major hepatectomy will experience intrahepatic recurrence after salvage RFA as well, and after similar time intervals. • About two-thirds of all patients develop new metastases elsewhere in the liver within 1 year after RFA. • However, long-term intrahepatic progression-free survival may still be achieved in some patients.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Zimmermann M, Pedersoli F, Schulze-Hagen M, et al. Salvage RFA in patients with intrahepatic recurrence after major hepatic surgery for colorectal cancer liver metastases: mid-term outcome. Eur Radiol. 2019. PMID: 31493210. doi:10.1007/s00330-019-06421-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。